Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-758P (RNA, U6 small nuclear 758, pseudogene) is one of many processed pseudogenes in the human genome derived from the U6 small nuclear RNA (snRNA) gene. U6 snRNA is a critical component of the spliceosome complex, catalyzing the excision of introns during pre-mRNA splicing in the nucleus[3][5]. Pseudogenes like RNU6-758P are formed by retrotransposition, typically mediated by LINE-1 elements, and are characterized by the absence of introns and the accumulation of mutations relative to the parental gene[9][1]. These pseudogenes are generally inactive, do not encode functional RNAs or proteins, and most lack any biological activity[9][3]. Large numbers of U6 snRNA pseudogenes are present in the genome, reflecting past retrotransposition events and emphasizing the evolutionary importance of U6 snRNA's role in splicing[9][3]. The specific numbering (758) indicates its sequential identification among many nearly identical U6 pseudogenes. There is no known clinical, pharmacological, or biomarker significance associated with RNU6-758P.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 758, pseudogene (RNU6-758P).